{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:27:57Z","timestamp":1787232477629,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:23:55Z","timestamp":1783974235000},"page":"1066-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymphome de Burkitt\u00a0: d\u00e9finition, diagnostic et prise en charge th\u00e9rapeutique actuelle"],"prefix":"10.1016","volume":"113","author":[{"given":"Morgane","family":"Gonin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Croizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9di","family":"Bensaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.04.013_bib0295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0065-230X(08)60470-4","article-title":"The pathogenesis of Burkitt's lymphoma","volume":"55","author":"Magrath","year":"1990","journal-title":"Adv Cancer Res"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.013_bib0300","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0305","series-title":"StatPearls [Internet]","article-title":"Burkitt lymphoma","author":"Naing","year":"2025"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0310","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241313083","article-title":"1990\u20132041\u00a0Global burden of Burkitt lymphoma with 20\u00a0years forecast: a systematic analysis using the global burden disease of study of 2021","volume":"13","author":"Dou","year":"2025","journal-title":"SAGE Open Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.013_bib0315","first-page":"1","article-title":"Lymphome de Burkitt","volume":"7","author":"Ribrag","year":"2012","journal-title":"EMC\u00a0\u2013\u00a0H\u00e9matologie"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.013_bib0320","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.013_bib0325","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2026.04.013_bib0330","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.2022016534","article-title":"Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma","volume":"141","author":"Thomas","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.013_bib0335","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","article-title":"Epstein-Barr virus and cancer","volume":"10","author":"Thompson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.013_bib0340","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1099\/0022-1317-68-11-2853","article-title":"New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas","volume":"68","author":"Young","year":"1987","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0345","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12985-022-01942-8","article-title":"Profiling genome-wide recombination in Epstein Barr virus reveals type-specific patterns and associations with endemic-Burkitt lymphoma","volume":"19","author":"Agwati","year":"2022","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0350","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1371\/journal.ppat.0030080","article-title":"A molecular link between malaria and Epstein-Barr virus reactivation","volume":"3","author":"Ch\u00eane","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ebiom.2018.12.041","article-title":"Epstein-Barr virus, malaria and endemic Burkitt lymphoma","volume":"39","author":"Velavan","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.013_bib0360","doi-asserted-by":"crossref","first-page":"e1004170","DOI":"10.1371\/journal.ppat.1004170","article-title":"A multifactorial role for P.\u00a0falciparum malaria in endemic Burkitt's lymphoma pathogenesis","volume":"10","author":"Torgbor","year":"2014","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.013_bib0365","doi-asserted-by":"crossref","first-page":"15678","DOI":"10.1002\/jcp.28219","article-title":"HIV-1\u00a0Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood","volume":"234","author":"Sall","year":"2019","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.013_bib0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.2024024765","article-title":"SOX11\u00a0in EBV-negative Burkitt lymphoma","volume":"144","author":"Piccaluga","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.013_bib0375","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2352-3026(24)00351-X","article-title":"Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet","volume":"12","author":"Ribrag","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.013_bib0380","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.13849","article-title":"The presence of genomic imbalances is associated with poor outcome in patients with Burkitt lymphoma treated with dose-intensive chemotherapy including rituximab","volume":"172","author":"Forero-Castro","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.013_bib0385","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/PAS.0000000000000365","article-title":"Expression profiles of MYC protein and MYC gene rearrangement in lymphomas","volume":"39","author":"Chisholm","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.013_bib0390","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ajcp\/aqv028","article-title":"MYC immunohistochemistry to identify MYC-driven B-cell lymphomas in clinical practice","volume":"145","author":"Kluk","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.013_bib0395","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.annonc.2024.06.003","article-title":"Human immunodeficiency virus-associated lymphomas: EHA\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"H\u00fcbel","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.013_bib0400","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.013_bib0405","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2018.207928","article-title":"Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma","volume":"104","author":"Gonzalez-Farre","year":"2019","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.bulcan.2026.04.013_bib0410","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2\u00a0and\/or BCL6\u00a0rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0415","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2141.2012.09026.x","article-title":"Burkitt lymphoma: staging and response evaluation","volume":"156","author":"Sandlund","year":"2012","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.bulcan.2026.04.013_bib0420","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.013_bib0425","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt Lymphoma International Prognostic Index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0430","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.013_bib0435","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt's\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2026.04.013_bib0440","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.013_bib0445","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0450","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10\u00a0trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.013_bib0455","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/S2352-3026(23)00279-X","article-title":"R-CODOX-M\/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON\/SAKK): final results of a multicentre, phase 3, open-label, randomised trial","volume":"10","author":"Chamuleau","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10036","key":"10.1016\/j.bulcan.2026.04.013_bib0460","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3\u00a0trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.013_bib0465","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3324\/haematol.2013.086827","article-title":"High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program","volume":"98","author":"Intermesoli","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.013_bib0470","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.bulcan.2026.04.013_bib0475","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.013_bib0480","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.013_bib0485","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.013_bib0490","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome\u2013related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.013_bib0495","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.013_bib0500","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u201cunclassifiable\u201d highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.04.013_bib0505","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.2023020168","article-title":"How I treat secondary CNS involvement by aggressive lymphomas","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0510","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"Classen","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.013_bib0515","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","article-title":"Antiviral prophylaxis in patients with solid tumours and haematological malignancies\u00a0\u2014\u00a0update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"94","author":"Sandherr","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0520","series-title":"StatPearls [Internet]","article-title":"Prevention of opportunistic infections in HIV\/AIDS (archived)","author":"Sadiq","year":"2025"},{"key":"10.1016\/j.bulcan.2026.04.013_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/BLCTT.S407804","article-title":"Refractory Burkitt lymphoma: diagnosis and interventional strategies","volume":"14","author":"Malfona","year":"2024","journal-title":"Blood Lymphat Cancer Targets Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0530","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.013_bib0535","doi-asserted-by":"crossref","first-page":"806.e1","DOI":"10.1016\/j.jtct.2025.06.004","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation in relapsed\/refractory B-cell non-Hodgkin lymphoma: an Italian Multicenter Collaborative Study","volume":"31","author":"Tarella","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.013_bib0540","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1007\/s00277-024-05979-3","article-title":"Early autologous and\/or allogeneic stem cell transplantation for adult patients with advanced stage T-lymphoblastic leukemia\/lymphoma or Burkitt lymphoma. A retrospective single-centre analysis","volume":"103","author":"Steiner","year":"2024","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.013_bib0545","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR-T cells induce a complete response in refractory Burkitt Lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2026.04.013_bib0550","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2023-184692","article-title":"CAR T-cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2026.04.013_bib0555","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1182\/blood-2024-194331","article-title":"Glofitamab in combination with R-ICE chemoimmunotherapy or as monotherapy in children and adolescents with relapsed\/refractory B-cell non-Hodgkin lymphoma: initial safety and efficacy results from the ongoing iMATRIX-GLO study","volume":"144","author":"Minard-Colin","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2026.04.013_bib0560","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMc2501018","article-title":"Glofitamab with polatuzumab vedotin in refractory Burkitt's lymphoma","volume":"392","author":"Prica","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bulcan.2026.04.013_bib0565","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V126.23.1558.1558","article-title":"PI3K\/Akt\/mTOR pathway inhibition in chemotherapy-sensitive and -resistant models of Burkitt lymphoma","volume":"126","author":"Bhatti","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.013_bib0570","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/1535-7163.MCT-16-0848","article-title":"Inhibition of Hsp90\u00a0suppresses PI3K\/AKT\/mTOR signaling and has antitumor activity in Burkitt lymphoma","volume":"16","author":"Giulino-Roth","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.013_bib0575","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2016-06-721423","article-title":"HSP90\u00a0promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.013_bib0290","first-page":"983","article-title":"Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K\/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101","volume":"93","author":"dos S Ferreira","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:57:38Z","timestamp":1787230658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0007455126003140"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphome de Burkitt\u00a0: d\u00e9finition, diagnostic et prise en charge th\u00e9rapeutique actuelle","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}